Moderna Stock News

Moderna Inc. applied on Wednesday to the United States Food and Drug Administration for its COVID-19 vaccine booster shot to be used for all adults in the country. Moderna applied for the extension f

Moderna has filed for Emergency Use Authorization (EUA) of its COVID-19 booster vaccine at the 50 µg dose level for all adults ages 18 and older with the U.S. Food and Drug Administration (FDA). On October 20, the FDA authorized for emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg [] The post Moderna asks FDA to authorize its COVID boosters for all adults appeared first on Breaking911 .

Pfizer, BioNTech, and Moderna are making thousands of dollars in combined profits every minute from their COVID-19 vaccines, while less than 1 percent of each companys doses have gone to the worlds poorest countries, according to a new analysis by the Peoples Vaccine Alliance (PVA). PVA, a coalition of organizations campaigning for wider access to COVID-19 vaccines, based its calculations []

Moderna (MRNA) shares fell again on Tuesday, but at least the move was small by recent standards. Moderna stock closed lower by just 0.34% at $234.28.

Moderna is seeking approval to use its COVID-19 vaccine in Canadian children six to 11 years of age. Health Canada confirmed Tuesday it has received a

Related Stocks: COF , BAC , CTLT , DGRS , IWM , MRNA , AMGN , CARR , PM , KKR , VTRS , NVS , AAL , BABA ,

Related Stocks: MRNA , AMD , LLY , NULV , NEE , NOW , WRBY , GE , EMXC , SPXT , DVY , IAU , PTC , SCI , VEEV , BIL , VRNS , TER ,

Moderna, Inc.''s (NASDAQ: MRNA ) vaccine franchise has further legs to play out, according to an analyst at Morgan Stanley. The Moderna Analyst: Matthew Harrison has an Equal-weight rating and a $313 price target for Moderna shares. The Moderna Thesis: The success of COVID-19 mRNA vaccines has led to the development of additional respiratory vaccines using the technology, Harrison said in a note. Related Link: Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates The next key vaccine readout, the analyst Full story available on Benzinga.com

After a magnificent run, Moderna (MRNA) stock has recently lost some of its luster. Over the past month some notable of events have resulted in the shares shedding

WASHINGTON: Pfizer, BioNTech and Moderna are making combined profits of $65,000 every minute from their highly successful Covid-19 vaccines while the worlds poorest countries remain largely unvaccinated, according to a new analysis. The companies have sold the vast majority of their doses to rich countries, leaving low-income nations in the lurch, said the Peoples Vaccine Alliance (PVA), a coalition campaigning for wider access to Covid vaccines, which based its calculations on the firms own earning reports. The Alliance estimates that the trio will make pre-tax profits of $34 billion this year between them, which works out to over $1,000 a second, $65,000 a minute or $93.5 million a day. It is obscene that just a few companies are making millions of dollars in profit every single hour, while just two percent of people in low-income countries have been fully vaccinated against coronavirus, Maaza Seyoum of the African Alliance and Peoples Vaccine Alliance Africa said. Pfizer, BioNTech and Moderna have used their monopolies to prioritise the most profitable contracts with the richest governments, leaving low-income countries out in the cold. Pfizer and BioNTech have delivered less than one percent of their total supplies to low-income countries while Moderna has delivered just 0.2 percent, the PVA said.

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction on Monday, November 15th. The shares were sold at an average price of $231.01, for a total transaction of $3,465,150.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Stephen Hoge []

Related Stocks: BX , IWD , AKTS , MRNA , AA , DKS , CLR , FTC , FRI , SPAB , SPLG , QQQ , FYT , FB , FANG ,

AstraZeneca (AZN) has revealed positive Phase IIa data from the EPICCURE trial of its injection AZD8601, which has been co-developed with Moderna (MRNA). The The post AstraZeneca, Moderna Disclose Positive Results from EPICCURE trial appeared first on Smarter Analyst .